Jukka Kemppainen

University of Turku — Finland

Medicine · Health Sciences

42h-index4.8kcitations187works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiovascular and exercise physiology(33), Prostate Cancer Treatment and Research(22), Prostate Cancer Diagnosis and Treatment(18), Virus-based gene therapy research(17), Cardiovascular Function and Risk Factors(17)

Publications187 total

Measuring the oncological value of exercise and statins (MOVES): Changing the tumour microenvironment with exercise and statins — an exploratory pilot trial
2026Open Access
Predictors of long-term survival for patients with pancreatic neuroendocrine neoplasm in FinPanNET: nationwide biobank study with histopathological re-evaluation
British journal of surgery·2025
Deep learning‐based 3D classification of head and neck cancer PET/MRI: Radiologist comparison and Grad‐CAM interpretability
Clinical Physiology and Functional Imaging·2025Open Access
Prospective comparison of 18F-PSMA-1007 PET/CT and MRI with histopathology as the reference standard for intraprostatic tumour detection and T-staging of high-risk prostate cancer
European Journal of Nuclear Medicine and Molecular Imaging·2025· 4 citedOpen Access
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 4 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 3 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Data from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Table 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Data from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 4 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Figure 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Pirjo Nuutila(25), Juhani Knuuti(25), Kari K. Kalliokoski(20), Marko Seppänen(13), Vesa Oikonen(12), Ivan Jambor(8), Heikki Minn(7), Ilkka Heinonen(7), Hannu J. Aronen(6), Johanna Hynninen(6), Sami Kajander(5), Tommi Noponen(5), Riitta Parkkola(5), Kirsi A. Virtanen(4), Anna Kuisma(4), Pauliina Luoto(4), Kalle Alanen(4), Toshihiko Fujimoto(4), Hannu Sipilä(4), Matti Luotolahti(4)